October 6, 2025 4:54pm

Lately news is not necessarily good news, and no news matters safely; by not releasing jobless report there is 2 less impediments in the market’s relentless rise.

As the cell and gene therapy sector gets profited by” uncle algo and his electronic trading dwarfs” have been scheming to sell into multiple session uplifts

Who speaks out while standing in-front, beside and behind investors - RMi

Never leave an investor uninformed!  

“I remain a skeptic, as electronic trading remains the impetus to, I believe a cell and gene therapy sector getting artificial high and low” … as proven in past sessions!

Monday’s RMi pre-open:   Despite … https://www.regmedinvestors.com/articles/14137

“When you’re riding’ ahead of the herd, take a look back every now and then to make sure your share pricing “cows” are moving”

 

Monday: The Dow closed DOWN -63.31 points or -0.14%, the S&P closed UP +24.49 points or +0.36% while the Nasdaq closed UP +161.161 points or +0.71%

  • Theme of the session: an increase in M&A, an Ai and bank deal while Home Depot and Verizon declined

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy

  • The ongoing shutdown increases the level of uncertainty and should incoming data deviate from the narrow ‘Goldilocks’ window, we suspect markets could be in for a bit of a rude awakening.” “That’s particularly true given how much of that ‘Goldilocks’ narrative we are pricing.” <Sherif Hamid, strategist Jefferies)

Monday’s (my) 40-company covered sector’s advance/decline line opened positive with 24 incliners, 15 decliners and 1 flat ending with a negative close of 17 incliners, 22 decliners and 1 flat

Metrics:  Monday, the RUT was up +10.18 points or +0.41%, the IBB was down -0.48 points or -0.32%, the XLV was down -0.70 points or -0.48%, the XBI was up +0.04 points or +0.04% while the VIX was down -0.270. points or -1.62% at 16.38

 

Q4 – 3 positive and 1 negative closes

Q3 – September - 1 holiday, 9 negative and 12 positive closes; August - 12 negative and 9 positive closes; July - 1 market holiday, 13 positive and 9 negative closes

 

Monday Closing UP (10 of 17) 

  • CRISPR Therapeutics (CRSP +$2.45 after Friday’s -$5.08),
  • Arrowhead Pharmaceuticals (ARWR +$1.38 after Friday’s +$1.52),
  • Vericel (VCEL +$1.30 after Friday’s +$0.92),
  • Sarepta Therapeutics (SRPT +$0.62),
  • Intellia Therapeutics (NTLA +$0.58 after Friday’s -$0.48),
  • Capricor Therapeutics (CAPR +$0.45 after Friday’s -$0.61),
  • Regenxbio (RGNX +$0.26 after Friday’s -$0.15),
  • Fate Therapeutics (FATE +$0.20),
  • Beam Therapeutics (BEAM +$0.14),
  • MiMedx (MDXG +$0.10 after Friday’s +$0.50)

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN),

Monday’s Closing DOWN (10 of 22): 

  • Alnylam Pharmaceuticals (ALNY -$4.35 after Friday’s -$4.64),
  • Lenz Therapeutics (LENZ -$2.63 after Friday’s +$0.42),
  • uniQure NV (QURE -$2.01 after Friday’s +$0.42
  • IQV Holdings (IQV -$1.59 after Friday’s +$2.29),
  • Mesoblast (MESO -$1.09 after Friday’s +$1.39),
  • Ultragenyx Pharmaceuticals (RARE -$1.02),
  • Moderna (MRNA -$0.95),
  • AxoGen AXGN -$0.72),
  • Solid Biosciences (SLDB -$0.42),
  • Vertex (VRTX -$0.40 after Friday’s -$5.55),

 

The Bottom Line: More of the … WHYs …

I can’t seem to let go of this quote, “It’s always darkest before the pitch dark”

Indexes ended Monday trading mixed, with the Dow slipping, the Nasdaq and S&P 500 clinching new record highs as the US government shutdown dragged on into its 6th day

The S&P 500 health care sector surged 6.8% last week to lead the index to record levels. That was the sector’s best weekly gain since the week of June 24, 2022, when it surged 8.2%.

  • I remain a skeptic, as electronic trading remains the impetus to, I believe the cell and gene therapy sector gets artificially … high and low” … as proven in past sessions by “uncle algo and his electronic trading dwarfs”!

The Russell 2000 (RUT) index recorded an all-time high today, rising about 1% to top the 2,500 level in morning trading; bringing its 6-month gain to nearly 37% and its year-to-date advance to more than 12%.

  • Keep your wallet closed!

 

October: understand the “flow” 

This week:

  • 10/6 – Monday closed negative with 17 positive, 22 negative and 1 flat

Last week:

  • 10/3 – Friday closed positive with 27 positive, 10 negative and 3 flats
  • 10/2 - Thursday closed positive with 26 positive, 13 negative and 1 flat
  • 10/1 – Wednesday closed positive with 26 positive, 14 negative and 0 flat
  • 9/30 -- Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 9/29 – Monday closed positive with 33 positive, 5 negative and 2 flats

The previous week:

  • 9/26 – Friday closed positive with 29 positive, 9 negative and 2 flats
  • 9/25 - Thursday closed negative with 8 positive, 30 negative and 2 flat
  • 9/24 – Wednesday closed positive with 28 positive, 11 negative and 1 flat
  • 9/23 – Tuesday closed negative with 7 positive, 32 negative and 1 flat
  • 9/22 – Monday closed positive with 31 positive, 9 negative and 0 flat

 

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: CRISPR Therapeutics (CRSP), Arrowhead Pharma (ARWR) and Vericel (VCEL)
  • Friday: IQV Holdings (IQV), Arrowhead Pharma (ARWR) and Mesoblast (MESO)

The worst three (3) in the session:

  • Monday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and uniQure NV (QURE)
  • Friday: Vertex (VRTX), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.